CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 76 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2020. The put-call ratio across all filers is 0.27 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,021,014 | -21.8% | 1,635,938 | -3.5% | 2.14% | -3.0% |
| Q2 2023 | $57,545,416 | -14.9% | 1,696,004 | -9.8% | 2.21% | -24.7% |
| Q1 2023 | $67,633,009 | -23.3% | 1,879,739 | -4.9% | 2.94% | -18.6% |
| Q4 2022 | $88,134,991 | +57.9% | 1,977,451 | -0.4% | 3.60% | +66.5% |
| Q3 2022 | $55,803,000 | -0.0% | 1,985,151 | -4.1% | 2.16% | +1.6% |
| Q2 2022 | $55,815,000 | -19.9% | 2,070,288 | +1.2% | 2.13% | -2.1% |
| Q1 2022 | $69,696,000 | -16.7% | 2,046,269 | -5.5% | 2.18% | +14.4% |
| Q4 2021 | $83,678,000 | -49.1% | 2,165,586 | -28.8% | 1.90% | -33.6% |
| Q3 2021 | $164,308,000 | +63.1% | 3,043,298 | +1.0% | 2.87% | +92.3% |
| Q2 2021 | $100,724,000 | +44.3% | 3,012,081 | -11.1% | 1.49% | +51.6% |
| Q1 2021 | $69,788,000 | +46.9% | 3,387,788 | +24.9% | 0.98% | +71.0% |
| Q4 2020 | $47,508,000 | +61.0% | 2,711,616 | +36.3% | 0.58% | +6.1% |
| Q3 2020 | $29,500,000 | +13.5% | 1,989,200 | -0.5% | 0.54% | +12.9% |
| Q2 2020 | $26,000,000 | – | 2,000,000 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 761,398 | $41,108,000 | 10.12% |
| Opaleye Management Inc. | 985,000 | $53,045,000 | 9.91% |
| VR Adviser, LLC | 1,098,174 | $59,290,000 | 7.62% |
| ACUTA CAPITAL PARTNERS, LLC | 337,500 | $18,222,000 | 6.43% |
| TSP Capital Management Group, LLC | 271,429 | $14,654,000 | 5.00% |
| Ghost Tree Capital, LLC | 255,000 | $13,767,000 | 4.03% |
| COMMODORE CAPITAL LP | 248,207 | $13,401,000 | 3.53% |
| RTW INVESTMENTS, LP | 3,908,947 | $211,044,000 | 3.18% |
| Ikarian Capital, LLC | 791,600 | $42,741,000 | 3.01% |
| Redmile Group, LLC | 3,043,298 | $164,308,000 | 2.87% |